Technology Transfer

Technology Transfer at the Medical Faculty

The Knowledge and Technology Transfer team at the Medical Faculty will help you turn initial ideas from applied research into real products that can benefit society. We work closely with the Transfer Center enaCom.

Our services and what we can do for you:

  • Support you in writing grant applications for transfer and innovation funding
  • Help you in preparing a winning pitch
  • Guide you in establishing a thorough business plan, including a business model, revenue model and go-to market approach
  • Advise you on regulatory and IP issues
  • Connect you with industry partners and potential investors

More than 50% of the scientists we support get funded. And we have helped science teams win more than 100,000 EUR from pitch competitions. Don't hesitate to contact us, we're excited to help.

Do you want to address medically relevant issues and bring your research or invention to the patient or doctor?

Send us a brief email to wissenschaft.transfer@ukbonn.de and we'll get back to you as soon as possible. We are happy to discuss any idea you may have.

What researchers say about working with us:

Dr. Katerina Deike-Hoffman
© UKB

"We had really helpful support from the Tech Transfer team in preparing for the 1st Medicine Pitch Contest. It was fun, our pitch improved a lot and we gained a better understanding of many other topics of the start-up phase such as financing, IP and market analysis. We now know that we can get valuable support here and will definitely stay in touch."

– Dr. Katerina Deike-Hofmann, Neuroradiology

Johannes Striebel
© UKB

"The Technology Transfer team at the Medical Faculty was very committed to advising us on all aspects of our project with their well-founded expertise. The valuable support - from writing the application for funding, preparing a one-pager to strategic considerations, have been essential to our success The change of perspective that they made possible for us was particularly helpful."

– Johannes Striebel, Experimental Ophthalmology

Arthur Jordan
© UKB

"In the intensive coaching of the Tech Transfer team, I learned how to create a really strong pitch presentation. In addition, various funding opportunities for my project were opened up to me. These are things that scientists may not have in mind and that my project develops took it to a whole new level."

– Arthur Jordan, Epileptology

Get in touch!

Avatar Worst

Eva Worst

Wissenschaftsmanagement - Transfer

Venusberg-Campus 1

53127 Bonn

Avatar Fasbender

Dr. Stefan Fasbender

Science Management - Transfer

Venusberg-Campus 1

53127 Bonn

Here is how to find us:

Deanship of the Medical Faculty
Venusberg-Campus 1, Building 33, 53127 Bonn
(right next to the canteen)

Newsletter Innovative Medicine

Sign up for the newsletter to receive information about:

  • Upcoming events
  • Funding programs
  • Important articles
  • Insipiring stories
  • Collaboration calls
Events
Makers of Tomorrow im SoSe 2024
Online
Whole Day
Deutschland braucht mehr Mut zum Gründen! Aus diesem Grund gibt es im Sommersemester wieder den Makers of Tomorrow Online-Kurs bei uns an der ...

Innovation Funding

Research & Incorporation Funding

Link: Go-Bio initial

Submission deadline: 15.02 of each year, BUT prior consultation with PROvendis necessary (no later than 15.01), so begin timely!

Focus: Life sciences

  • Therapeutics
  • Diagnostics
  • Medical technology
  • Platform technologies
  • Research tools

Funding:

  • Exploratory phase: Personnel, travel, consulting services, patent applications / FtO analysis, material and consumables, up to 100,000 euros.
  • Feasibility phase: Staff, travel, consulting services, patent applications / FtO analysis, material and consumables, subcontracts, up to 1,000,000 euros.

Duration:

  • Exploratory phase: Up to 12 months
  • Feasibility phase: Up to 24 months

Link: Go-Bio next

Submission deadline:

  • 15.03. every year
  • 15.09. every year

Focus: Life sciences

  • Drug and vaccine development
  • Novel platform technologies for drug development
  • Complex medical devices in risk class 3
  • In-vitro diagnostics in risk class D
  • Companion diagnostics
  • Combination products consisting of a medical device and a drug

Funding:

  • Phase I: N/A
  • Phase II: N/A

Duration: N/A

Link: Start-interaktiv

Submission deadline: 15.01 and 15.07

Focus:

  • Digitally supported health and care
  • Liveable spaces: smart, sustainable and innovative

Funding:

  • Module 1: Eligible for funding are expenditures for the implementation of R&D projects (personnel, material and travel expenditures as well as project-related investments that are not attributable to the applicant's basic equipment). No maximum funding amount has been specified (we recommend the range around 400,000 euros).
  • Module 2: In the case of startups with little capital, it is checked whether funding of eligible project-related expenses, usually 80%, could be necessary. Maximum funding: 400,000 euros.

Duration: 18-36 months

Link: Validierungsförderung VIP+

Submission deadline: Continuous application possible

Focus: Topic agnostic

Funding: Up to 1,500,000 euros

Duration: Up to 36 months

Link: EXIST-Forschungstransfer

Submission deadline:

  • Continuous application possible
  • Project evaluation takes place starting 31.04., 31.08. and 30.11. every year

Focus: Topic agnostic

Funding:

  • Phase 1: From 500,00 up to 1,500,000 euros. Personnel expenses / costs for a maximum of four personnel positions as well as material expenses / costs are financed. The material expenses / costs include, for example, commodities, consumables, capital goods, property rights, market research and the awarding of orders and coaching measures. Student assistants can also be funded. The expenses/costs for student assistants and material expenses/costs are generally eligible up to a total of 250,000 euros. Projects of the research institutions of the FhG, HGF, Max Planck Society, Leibniz Association that are jointly funded by the federal and state governments can be funded up to 90%, those of universities and other research institutions up to 100%.
  • Phase 2: Non-repayable subsidy of up to 180,000 euros, but no more than 75% of the specific costs of the project. As a prerequisite for funding, the company provides its own funds and, if necessary, equity capital in a ratio of 1:3 (up to 60,000 euros).

Duration:

  • Phase 1: 18 - 36 months
  • Phase 2: 18 months

Link: EXIST-Gründerstipendium

Submission deadline: Continuous application possible

Focus: Topic agnostic

Funding:

  • Founders with a doctorate degree: 3,000 euros/month
  • Graduates with a university degree: 2,500 euros/month
  • Technical employees: 2,000 euros/month
  • Students: 1,000 euros/month
  • Child supplement: 150 euros/month per child
  • Material expenses: up to 10,000 euros for individual start-ups (max. 30,000 euros per team)

Duration: 12 months

Link: KMU-innovativ

Submission deadline: Depends onthe individual technology field

Focus:

  • Bioeconomy
  • Electronics and autonomous driving
  • Supercomputing
  • Research for civil security
  • Medical technology
  • Information-and communicationtechnologies
  • Interactive technologies for health and quality of life
  • Material research
  • Photonics and quantum technologies
  • Production technology
  • Resource efficiency and climate protection

Funding: 20 to 100% of the eligible costs, depending on applicants and type of costs

Duration: N/A

Link: ERC Proof of Concept

Submission deadline:

  • 14.03.2024
  • 17.09.2024

Focus: Only PIs from one of the ERC main grants (Starting, Consolidator, Advanced, Synergy) may apply.

Funding: 150,000 euros

Duration: 18 months

Link: EIC Pathfinder Open & Challenges

Submission deadline:

  • 07.04.2024
  • 17.10.2024

Focus: EIC Pathfinder Open is open to all topics. New topics are published for the EIC Pathfinder Challenges every year. Consortia are usually required for EIC Pathfinder Open, but individual applications are also permitted for EIC Pathfinder Challenges.

Funding: up to 4,000,000 euros

Duration: N/A

Link: EIC Transition Open & Challenges

Submission deadline:

  • 18.09.2024

Focus: EIC Transition Open is open to all topics. New topics are published for EIC Transition Challenges every year. Only projects that are funded with EIC Pathfinder, ERANET FET programs or ERC Proof of Concept may apply.

Funding: up to 2,500,000 euros

Duration: up to 36 months

Tips

  • Most funding programs are topic-independent and accept projects from the areas of therapeutics, medical technology, biotechnology, diagnostics and digital health.

  • Individual projects are usually 100% funded, while industrial collaborations (be it with a startup or a larger company) require partial self-financing between 10% and 50%.

  • Some programs require a legal entity based in NRW.

  • We would be happy to help you choose the right funding program for your stage and needs.

What researchers say about working with us:

Julia Pawlick
© UKB

“I found our cooperation more than helpful! What was particularly great was simply the absolute willingness to help and quick responses to questions, especially about the pitch contest. The detailed information about the investors who were to be present was super helpful in order to be able to optimally prepare the pitch deck and also to be able to prepare for possible questions. Going through the grant options with us to get the best possible result was also very helpful. That is simply incredibly motivating and you just feel super supported. In addition, the conversations and meetings were always super pleasant and you just felt that you were in good hands, especially as a person."

– Julia Pawlick, Experimental Ophthalmology

Startup or license?

Each approach has its advantages and challenges. We’ll help you develop a commercialisation strategy that fits your invention. Contact us!

Inventions & Patents

IP Protection & Licensing

Do you have an idea that might have widespread application? Disclosing your invention is a crucial first step towards protecting your interests and your innovation’s potential.

    How to get started

    There is some initial information we need before we can prepare your invention disclosure. This helps us to determine the ownership of the invention, the scope of patent protection, which inventors should be put on a patent application and more. Here is an overview:

    • General information about the invention
    • Information concerning the inventor(s)
    • Description of the invention
    • Description of the market
    • Additional results
    • Confirmation of the inventor(s)
    • Confirmation of the university
    • Assignment of PROvendis*

    To provide us with this information please download the Standard Invention Disclosure or the Software Invention Disclosure, fill it in and send it to us following the instructions inside. If you need help in any way, please don't hesitate to contact us.

    Note: While it is important to include the required information in pursuit of completing this form, please do not delay your submission due to a lack of simple, granular information (e.g., an address). These types of details can be collected later in the process.

    Note: Making a public disclosure before patent filing may jeopardize our ability to protect your IP.

    *As the official patent service for NRW universities we closely work with PROvendis GmbH for all invention disclosures, patent applications and licensing deals.

    Protect your intellectual property when collaborating with third parties, whether they are non-profit or for-profit institutions.

    MTAs specify the rights, obligations and restrictions of both the providing and receiving parties with respect to issues such as ownership, publication, intellectual property and permitted use and liability.

    All contracts need to be presented to the responsible internal team and have to be checked and approved by them. Please reach out to Martin Trillsch, or alternatively contact us.

    Different inventions require different licensing strategies. For example, a basic new scientific tool that is likely to be widely used is typically licensed on a non-exclusive basis. In contrast, an invention which requires significant investment of resources by a company is typically licensed on an exclusive basis. The exclusive license provides the licensee with an incentive to undertake the risky capital investments and commit the resources required for product development.

    Key starting points for customising a licensing approach for each entity include knowing:

    • The product benefits relative to existing products
    • The expected customers
    • Market channels
    • Potential sales and margins
    • Additional aspects of the proposed or existing business

    Standard features of a license will typically include negotiated financial terms, such as annual fees, milestone fees, a royalty on product sales and reimbursement of patent costs. The non-financial terms of the license are equally important and will include:

    • Degree of exclusivity: nonexclusive, exclusive, or restricted by field of use
    • Reservation of rights for the federal government (if the invention is derived from federally-funded research) and for the University and other non-profit organizations for their research and educational activities
    • Performance (or “diligence”) requirements to assure that the company has the resources to develop the technology and is committed to doing so. These diligence terms allow for tracking the progress of the technology toward commercialisation.

    1. Invention Disclosure. The inventors provide a description of the technology and an explanation of the critical solution it could provide to benefit society by submitting an Invention Disclosure Form. This is the first step of the Patent Application preparation process.

    2. Preliminary Invention Assessment. Each disclosure is evaluated for commercial potential and patentability by NRW's specialised service provider PROvendis. Factors considered include:

    • Novelty
    • Inventive approach
    • Manufacturing feasibility
    • Potential applications
    • Market size
    • Potential competitors/partners
    • Potential challenges to patenting and commercialisation

    According to the Arbeitnehmererfindergesetz PROvendis has four months from the time of notification to consider the chances that a technology can be successfully patented or licensed before investing in the cost of obtaining patent protection (approximately 30.000 – 45.000 EUR in Germany alone).

    If PROvendis decides to make a claim, it is obliged to file a patent application with the inventors in Germany and to pay inventor remuneration in the event of financial exploitation (see Royalty Sharing below). If PROvendis decides against it, the invention is released and the inventors are allowed to file by themselves.

    3. Patent Application. To obtain a patent, PROvendis files an official request for examination with the DPMA and starts a process that may take up to 2.5 years. If the result of the examination is positive, the patent owner is granted the exclusive right to exploit the invention for a maximum period of 20 years.

    4. Invention Commercialisation. The main goals are to ensure that the technology will be used for the public benefit, complying with federal and University policies and if successful will provide a reasonable financial return to the University and the inventors. Few possibilities exist for the commercialisation of patents such as:

    • Licensing agreements
    • Raising third party funding
    • Starting a business

    The approach may vary on case by case basis and will depend on various factors, including the interest of the market. PROvendis and the University will market the technology to companies and organisations who might be interested in dedicating money, people and resources to develop it for broader use.

    5. Royalty Sharing. In the case of the successful commercialisation of the patent application, following the University's Patent Strategy the gross income or royalties are divided the following way:

    • 30% goes to the inventors
    • 5-15% goes to PROvendis, depending on the gross income

    The University uses the remaining income to refinance the patenting costs as well as transfer-related activities and to incentivise the Institute of the inventors.

    In the case of multiple inventors, the University will divide the inventors' share equally unless all the inventors have agreed to a different allocation.

    Who is an inventor? Unlike authorship on a research publication, inventorship is a legal determination made by a patent attorney. An inventor on a patent is someone whose ideas and experimentation are responsible for (or substantially contributed to) the conception of an invention. In a university setting, inventors might include the faculty member in whose lab the IP originated, students or postdocs who carried out work in the lab, and collaborators or others who contributed to the invention.

    What can be patented? To be patentable, an invention must be useful, novel, and not obvious.

    • Compositions of matter – new chemical or biological entities, but not isolated products of nature
    • Machines – mechanical or electronic devices, including medical devices
    • Articles of manufacture – new products made by defined process
    • Processes – methods of making compositions, methods of making articles, and even some methods of gathering or evaluating data or of performing business

    Researchers also generate other types of intellectual property in addition to inventions, such as copyrightable creations, including content-based scholarly works, and unpatented materials, such as cell lines.

    Who owns what I create? Ownership depends upon the employment status of the creators of the invention and their use of University resources. Considerations include:

    • What was the creator's employment status at the time the intellectual property was made?
    • Were University resources used in creating the intellectual property?
    • What are the terms of any agreement related to the creation of the intellectual property?

    As a general rule, the University owns inventions conceived or reduced to practice in whole or in part by members of the faculty or staff (including student employees) of the University in the course of their University responsibilities or with more than incidental use of University resources.

    What researchers say about working with us:

    Behnam Javanmardi
    © UKB

    "I have given many scientific talks, but preparing a pitching presentation was very different. The trainings made me think about some business aspects of our project that I didn’t know that I didn’t know! It was a fantastic crash course!"

    – Dr. Behnam Javanmardi, Institute for Genomic Statistics and Bioinformatics

    Attention!

    Our ability to protect IP falls in jeopardy if you publish, present, or share your findings with others on a non-confidential basis before we file a patent application. If you plan to disclose any information about your innovation to others, please contact us immediately.

    Startups & Spin-Offs

    For Founders

    Launching a startup company can be an exciting and fulfilling opportunity. We can help you analyze several factors to determine whether this is the most appropriate path to commercialisation for your technology, including:

    • The potential of the core technology to provide a solid platform for multiple markets or product opportunities
    • The competitive environment
    • Likelihood of interest from existing companies in licensing the technology
    • Availability of venture capital, together with the interest, capabilities, and track record of likely investors
    • And more

    Here is a list of startups from Uni Bonn.

    We are here to help. This help can take various forms and cover many directions, including:

    • Set up a collaboration between the university and industry
    • Provide expertise in various technology, business, legal and leadership fields
    • Help you find application for your invention
    • Help you protect your invention
    • Help you apply for grants and VC funding
    • Help you start your own company

    To get started just contact us.

    There are few popular routes when it comes to getting funding for an academic startup.

    Grants. Involves the borrowing of money without the obligation to repay them. Grants are, essentially, a gift. See Innovation Funding section above for a list of grants we can help you apply for.

    Equity financing. Involves selling a portion of a company's equity in return for capital. The main advantage of equity financing is that there is no obligation to repay the money acquired through it in case of a failure. The downside is that one has to consult with the new partners any time one makes decisions affecting the company.

    Equity financing is the most popular financing path for startups with innovative solutions. It usually requires getting initial market traction and showing some product/market fit proof.

    More common forms of equity financing include:

    • Angel investors
    • Crowdfunding
    • Venture capital firms (VC)
    • Corporate investors
    • Listing on an exchange with an initial public offering (IPO)

    Debt financing. Involves the borrowing of money and paying it back with interest. The advantages of debt financing include retention of control over your business, tax deductible interest payments and predictability. The downside to debt financing is that it is a bet on ones future ability to pay back the loan.

    More common forms of debt financing include:

    • Term loans
    • Business lines of credit
    • Personal loans, usually from a family or friend
    • Peer-to-peer lending services

    There are various regional and national startup pitching contests with prizes ranging from 1.000 to 100.000 EUR. A collection can be found on few websites, including:

    Some of the more popular ones focused on medicine are here:

    March:

    April:

    June:

    August:

    September:

    Note: You can keep your invention a secret and still participate in a startup competitons. We can help you with that. Get in touch with us.

    Got questions? Send them over to wissenschaft.transfer@ukbonn.de.

    What researchers say about working with us:

    Ines Guetgemann
    © UKB

    "What helped me most were the specific recommendations on how to present, business aspects that I was unaware of, the excellent support in a very short time frame and the broad expertise in the biotech and investment sector. The Tech Transfer team at the Medical Faculty has given me excellent hands on advice and I am looking forward to working with them in the near future!"

    – Prof. Ines Gütgemann, Pathology

    Theodor Rueber
    © UKB

    "The 1st Medical Pitch Contest and above all the fantastic preparatory offer for it by the Tech Transfer team from the Medical Faculty opened up a previously unknown door for our research work. Regardless of whether we go through it or not, it was a great enrichment."

    – Dr. Theodor Rüber, Epileptology

    Thomas Ach
    © UKB

    "What helped me was the targeted preparation for the format of the 1st Medical Pitch Contest, the focus on investor ideas and the differentiation from "conventional" scientific lectures, as well as the detailed knowledge, background and critical questions."

    – Dr. Thomas Ach, Experimental Ophthalmology

    Memories from the 2nd Medicine Pitch Contest at the MIB Future Panel 2023

    Pitch Contest of the Medical Faculty
    © Volker Lannert/Uni Bonn

    Recent news and successes:

    Früherkennung von Sehverlust bei altersabhängiger Makuladegeneration (AMD)

    Neue Untersuchungen des Universitätsklinikums Bonn (UKB) in Kooperation mit der Universität Bonn haben erstmals gezeigt, dass bestimmte frühe Veränderungen bei Patientinnen und Patienten mit altersabhängiger Makuladegeneration (AMD) zu einem messbaren lokalen Verlust der Sehfähigkeit führen können. Diese Entdeckung könnte zukünftig helfen, die Behandlung und Überwachung dieser ansonsten langsam zur zentralen Erblindung führenden Augenerkrankungen bei älteren Patientinnen und Patienten zu verbessern und neue Therapien zu testen.

    Finde Deine Mitgründer*innen: Gesucht? Gefunden! Gegründet 🚀

    Du hast eine innovative Idee und suchst nach Mitgründer*innen für Dein Start-up? Oder trägst Du den Gründungsspirit in Dir, aber suchst noch nach einem Projekt, in dem Du Dich einbringen kannst? Auf der Plattform FoundFactory werden Ideengeber*innen und Gründungsinteressierte passgenau gematcht. Das Transfer Center enaCom bietet ab Juli für ein Jahr allen Angehörigen der Uni Bonn einen kostenlosen Zugang zu den Services von FoundFactory an. Das Besondere ist, dass dabei nicht nur fachliche Interessen, sondern auch persönliche Eigenschaften berücksichtigt werden und Ihr so sicher sein könnt, Euer Dream Team für ein erfolgreiches Start-up zu finden.

    Neue Perspektiven für Patientinnen und Patienten

    Das Berlin Institute of Health in der Charité (BIH) hat kürzlich die Nationale Strategie für gen- und zellbasierte Therapien an die Bundesforschungsministerin Bettina Stark-Watzinger (FDP) übergeben. Rund 150 Expert*innen – darunter zwei Forschende des Universitätsklinikums Bonn (UKB) und der Universität Bonn – haben das Papier erarbeitet und einen Fahrplan zur Verbesserung der Krankenversorgung und Stärkung des Standorts Deutschland im Bereich der gen- und zellbasierten Therapien entwickelt.

    Auszeichnung für Medikamenten-Forschung zu Flussblindheit und Elefantiasis

    Das A∙WOL-Team wurde jetzt von der Royal Society of Chemistry für die Entdeckung von potentiell schnell wirkenden, hochspezifischen Anti-Wolbachia-Kandidaten für die orale Behandlung der menschlichen Filariose mit dem Horizon Prize 2024 ausgezeichnet. Das Team ist eine Kooperation zwischen der Universität Liverpool, der Liverpool School of Tropical Medicine, dem Imperial College London, dem Universitätsklinikum Bonn (UKB) und der Universität Bonn sowie Industriepartnern von Astra Zeneca und Eisai Ltd, die viele Jahre von der Gates Foundation gefördert wurde. Vom UKB und der Universität Bonn werden Prof. Achim Hörauf und Prof. Marc Hübner für ihren Anteil an der Arbeit im Kampf gegen seltene Tropenkrankheiten ausgezeichnet.

    Neue Therapieform mit gespiegelter RNA gegen hochaggressive Hirntumore wirksam

    Glioblastome sind besonders aggressive Hirntumore, die schnell auch in das gesunde Hirngewebe hineinwuchern. Da die Tumore chirurgisch meist nicht vollständig entfernt werden können, ist die Prognose von Glioblastom-Patientinnen und Patienten sehr schlecht. Die Standardtherapie – bestehend aus einer Kombination von Operation, Bestrahlung und Chemotherapie – verspricht keine Heilung. Mit Hochdruck wird daher nach erfolgreichen Behandlungsmöglichkeiten gesucht. Wissenschaftler der Universitätsmedizin Mannheim (UMM), des DKFZ-Hector Krebsinstitutes an der UMM und des Universitätsklinikums Bonn (UKB) erforschen eine neue Therapie mit einer neuartigen Medikamentenklasse von gespiegelten RNA-Polymeren, sogenannten Spiegelmeren, die die Regeneration des Glioblastoms blockieren soll.

    Neue Leiterin der Ataxieambulanz am UKB erhält Pioneer SCA3 Translational Research Award

    Dr. Jennifer Faber, seit März 2024 neue Leiterin der Spezialambulanz für Ataxien am Universitätsklinikum Bonn (UKB) und Wissenschaftlerin am Deutschen Zentrum für Neurodegenerative Erkrankungen (DZNE), wurde von der US-amerikanischen National Ataxia Foundation (NAF) mit dem „Pioneer SCA3 Translational Research Award“ ausgezeichnet. Die Auszeichnung ist mit 100.000 US-Dollar dotiert und wurde Dr. Faber für die Weiterentwicklung eines von ihr etablierten datenbasierten Stadienmodells der genetisch vererbten Spinozerebellären Ataxie Typ 3 (SCA3) verliehen. Das UKB ist mit seiner Spezialambulanz seit Jahren ein wichtiges Zentrum der Versorgung von Menschen mit Ataxien und in Zusammenarbeit mit dem DZNE eine treibende Kraft in der Erforschung dieser Hirnerkrankungen. Die Leitung der Ambulanz hatte Dr. Faber im März 2024 übernommen, nachdem Prof. Klockgether als langjähriger Direktor der Klinik für Neurologie am UKB ausgeschieden war.

    Durchbruch in der Forschung über braunes Fett

    Forschende des Universitätsklinikums Bonn (UKB), der Universität Bonn, der Universität Süddänemark und das Novo Nordisk Center for Adipocyte Signaling (SDU) haben ein Protein gefunden, das für die Abschaltung der Aktivität des braunen Fettes verantwortlich ist. Diese neue Entdeckung könnte zu einer vielversprechenden Strategie zur sicheren Aktivierung des braunen Fettgewebes und zur Bekämpfung von Fettleibigkeit und damit verbundenen Gesundheitsproblemen führen. Die Ergebnisse der Studie sind jetzt im Fachmagazin „Nature Metabolism“ veröffentlicht.

    Vereinfachte Diagnose seltener Augenerkrankung

    Uveitis ist eine seltene entzündliche Augenerkrankung. Vor allem die posteriore und die Panuveitis sind mit einer schlechten Prognose und einem langwierigen Krankheitsverlauf assoziiert. Die Diagnose und das Monitoring können für das ärztliche Fachpersonal herausfordernd sein. Die Fundusautofluoreszenz (FAF) ist ein schnelles und nicht-invasives bildgebendes Verfahren, das hierbei unterstützt. Forschende des Universitätsklinikums Bonn und der Universität Bonn haben nun gemeinsam mit Fachleuten aus Berlin, Münster und Mannheim eine Übersichtsarbeit dazu verfasst, wie die FAF die Diagnosestellung und das Monitoring von posteriorer Uveitis und Panuveitis erleichtern kann. Die Ergebnisse sind jetzt im Fachmagazin „Biomolecules“ erschienen.

    150+

    Professors at the Medical Faculty

    650+

    Fundings Closed

    Commercial Possibilities

    Wird geladen